MX2009006378A - Biomarcadores para cancer. - Google Patents

Biomarcadores para cancer.

Info

Publication number
MX2009006378A
MX2009006378A MX2009006378A MX2009006378A MX2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A
Authority
MX
Mexico
Prior art keywords
biomarker
cancer biomarkers
peptide
prostate cancer
cancer
Prior art date
Application number
MX2009006378A
Other languages
English (en)
Spanish (es)
Inventor
Hardev Pandha
Richard George Leonard Morgan
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of MX2009006378A publication Critical patent/MX2009006378A/es

Links

Classifications

    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
MX2009006378A 2006-12-19 2007-12-19 Biomarcadores para cancer. MX2009006378A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (1)

Publication Number Publication Date
MX2009006378A true MX2009006378A (es) 2009-08-24

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006378A MX2009006378A (es) 2006-12-19 2007-12-19 Biomarcadores para cancer.

Country Status (19)

Country Link
US (1) US8460882B2 (enExample)
EP (1) EP2115472B1 (enExample)
JP (1) JP5683108B2 (enExample)
CN (1) CN101675341B (enExample)
AU (1) AU2007335999B2 (enExample)
BR (1) BRPI0720371B8 (enExample)
CA (1) CA2671939C (enExample)
CY (1) CY1115178T1 (enExample)
DK (1) DK2115472T3 (enExample)
ES (1) ES2445185T3 (enExample)
GB (2) GB0625321D0 (enExample)
IL (1) IL199241A (enExample)
MX (1) MX2009006378A (enExample)
NZ (1) NZ577548A (enExample)
PL (1) PL2115472T3 (enExample)
PT (1) PT2115472E (enExample)
RU (1) RU2460075C2 (enExample)
SI (1) SI2115472T1 (enExample)
WO (1) WO2008075056A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
JP2012532621A (ja) * 2009-07-13 2012-12-20 ザ ユニバーシティ オブ サリー 治療ペプチド、ポリペプチド及び核酸配列
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
US20140336130A1 (en) * 2011-12-05 2014-11-13 Phigenix, Inc. Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
WO2014005138A1 (en) * 2012-06-29 2014-01-03 Kerschensteiner Daniel A Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
EP2994753B1 (en) * 2013-05-09 2018-03-07 The Procter and Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP3303616B1 (en) * 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP3960195B1 (en) * 2015-09-23 2025-01-08 Centre national de la recherche scientifique Engrailed for treatment of amyotrophic lateral sclerosis
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
EP3564365B1 (en) * 2016-12-28 2023-01-25 Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences Transdifferentation of b lymphoid cells into t cells
KR101777085B1 (ko) * 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295303A1 (en) * 1997-06-27 1999-01-07 Human Genome Sciences Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
JP2002527758A (ja) * 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
WO2001092879A1 (en) 2000-05-30 2001-12-06 Danmarks Miljø Undersøgelser An assay method and kit for testing biological material for exposure to stress using biomarkers
EP1297182A2 (en) * 2000-06-30 2003-04-02 Epigenomics AG Diagnosis of diseases associated with cell signalling
US20050079492A1 (en) * 2000-09-12 2005-04-14 Burgess Jr. Robert M. Micro-arrayed organization of transcription factor target genes
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
WO2002054936A2 (en) 2000-12-24 2002-07-18 Kohn, Kenneth, I. A method for detecting biomarkers
WO2002070742A1 (en) * 2001-03-01 2002-09-12 Epigenomics Ag Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP1831399B1 (en) * 2004-12-02 2009-08-05 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
WO2006089091A2 (en) * 2005-02-18 2006-08-24 Memorial Sloan-Kettering Cancer Center Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
BRPI0720371A2 (pt) 2013-12-31
WO2008075056A1 (en) 2008-06-26
AU2007335999B2 (en) 2013-09-05
JP5683108B2 (ja) 2015-03-11
EP2115472A1 (en) 2009-11-11
IL199241A (en) 2014-03-31
AU2007335999A1 (en) 2008-06-26
US8460882B2 (en) 2013-06-11
GB0625321D0 (en) 2007-01-24
PL2115472T3 (pl) 2014-05-30
BRPI0720371B1 (pt) 2019-05-28
CN101675341A (zh) 2010-03-17
SI2115472T1 (sl) 2014-05-30
JP2010513901A (ja) 2010-04-30
EP2115472B1 (en) 2013-11-06
DK2115472T3 (da) 2014-02-10
ES2445185T3 (es) 2014-02-28
PT2115472E (pt) 2014-02-14
BRPI0720371B8 (pt) 2021-07-27
GB0719792D0 (en) 2007-11-21
CN101675341B (zh) 2017-08-08
CY1115178T1 (el) 2016-12-14
US20100093558A1 (en) 2010-04-15
RU2460075C2 (ru) 2012-08-27
RU2009127774A (ru) 2011-01-27
CA2671939A1 (en) 2008-06-26
NZ577548A (en) 2012-03-30
CA2671939C (en) 2017-10-03

Similar Documents

Publication Publication Date Title
MX2009006378A (es) Biomarcadores para cancer.
IL200487A0 (en) Method and apparatus for detecting computer fraud
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
ES2570359T3 (es) Regiones ultraconservadas que codifican ARNnc
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
CO7160023A2 (es) Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática
IL233098A (en) Methods for detecting cancer and determining prognosis and survival probabilities and ratio based biomarkers for use therein
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
CL2007001623A1 (es) Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
WO2008128169A8 (en) Sparc and methods of use thereof
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
AR055316A1 (es) Metodos para la identificacion de tumores que responden al tratamiento con inhibidores de dimerizacion de her (hdis)
CR20120298A (es) Antagonistas de il-17a
AR060228A1 (es) Diagnosticos y tratamientos para tumores
EP4328589A3 (en) Cancer biomarkers
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
MX2009008247A (es) Biomarcadores de respuesta a la radiacion ionizante.
EP4513187A3 (en) Methods of detecting prostate cancer
CL2015002572A1 (es) Marcadores asociados con inhibidores de wnt

Legal Events

Date Code Title Description
FG Grant or registration